{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-046419","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.531299+00:00","generated_at":"2026-06-01T08:36:11.401402+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ABVC licenses MDS drug BLEX 404 to OncoX; eligible for $13.75M in fees plus royalties","bullets":["ABVC and subsidiary BioLite grant OncoX exclusive rights to develop/commercialize BLEX 404 for MDS in 50% of global markets for 20 years.","Upfront license fee of $12.5M (cash or OncoX shares) due in 30 days; additional $1.25M milestone after OncoX's next fundraising (no guarantee).","ABVC entitled to 5% royalties on net sales, capped at $12.5M, after product launch (uncertain).","BLEX 404 is a β-glucan extract from Maitake mushroom; FDA has approved four INDs for ABVC's oncology pipeline including ABV-1702 for MDS.","No guarantee any fees or royalties will be received; partnership is early-stage and contingent on OncoX's fundraising and commercial success."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-046419","json":"https://secwatch.observer/filing/0001213900-24-046419.json","markdown":"https://secwatch.observer/filing/0001213900-24-046419.md","text":"https://secwatch.observer/filing/0001213900-24-046419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024046419/0001213900-24-046419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024046419/ea0206790-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:36:11.401402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}